The widespread prevalence of @entity6 , caused by @entity73 and insulin resistance, is now a worldwide health problem. @entity5445 ( @entity5445 ) is a major intestinal hormone that stimulates @entity413 -induced insulin secretion from b cells. Prolonged activation of the @entity5445 signal has been shown to attenuate @entity6 in animals and @entity1 subjects. Therefore, @entity5445 secretagogues are attractive targets for the treatment of @entity6 . Recent epidemiological studies have reported that an increase in daily coffee consumption lowers @entity6 risk. The present study examined the hypothesis that the reduction in @entity6 risk associated with coffee consumption may be mediated by the stimulation of @entity5445 release by coffee @entity3978 extract (CPE). @entity5445 secretion by @entity1 enteroendocrine @entity1 cells was augmented in a dose-dependent manner by the addition of CPE, and was compatible with the increase in observed active @entity5445 (7-36) @entity6346 levels in the portal blood after administration with CPE alone in @entity19 . CPE increased intracellular @entity1919 ( @entity268 ) levels in a dose-dependent manner, but this was not mediated by @entity64635 ( @entity64635 ). The oral administration of CPE increased diet (starch and @entity31356 )-induced active @entity5445 secretion and decreased @entity413 -dependent insulinotropic polypeptide release. Although CPE administration did not affect diet-induced insulin secretion, it decreased postprandial hyperglycaemia, which indicates that higher @entity5445 levels after the ingestion of CPE may improve insulin sensitivity. We conclude that dietary coffee @entity6398 augment gut-derived active @entity5445 secretion via the @entity268 -dependent pathway, which may contribute to the reduced risk of type 2 @entity6 associated with daily coffee consumption.

Ingestion of coffee @entity6398 increases postprandial release of the active glucagon-like peptide-1 (GLP-1(7-36)) @entity6346 in C57BL/6J XXXX .

@entity1 :: ('9606', 'Species') :: ['human', 'NCI-H716'] @entity3978 :: ('CHEBI:26195', 'Chemical') :: ['polyphenol'] @entity268 :: ('CHEBI:17489', 'Chemical') :: ['cAMP'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes'] @entity19 :: ('10090', 'Species') :: ['mice'] @entity73 :: ('MESH:D003072', 'Disease') :: ['impaired insulin secretion'] @entity64635 :: ('139760', 'Gene') :: ['GPR119', 'G protein-coupled receptor 119'] @entity1919 :: ('MESH:D000242', 'Chemical') :: ['cyclic AMP'] @entity6398 :: ('MESH:D059808', 'Chemical') :: ['polyphenols'] @entity31356 :: ('CHEBI:53753', 'Chemical') :: ['glyceryl trioleate'] @entity6346 :: ('CHEBI:32988', 'Chemical') :: ['amide'] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose'] @entity5445 :: ('2641', 'Gene') :: ['Glucagon-like peptide 1', 'GLP-1']
@entity19 :: (10090,Species) :: ['mice']
